Zhiben Pharma

Zhiben Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs. The company leverages its proprietary Targeted Protein Degradation (TPD) platform, including PROTAC and molecular glue technologies, to address unmet medical needs in oncology and immunology. Its lead candidate, ZB001, is a potent BTK degrader currently undergoing clinical evaluation for the treatment of B-cell malignancies. Zhiben Pharma aims to overcome drug resistance associated with traditional inhibitors by utilizing the body's natural protein disposal system. The company is backed by prominent venture capital firms and maintains a robust pipeline of early-stage programs targeting high-value oncogenic drivers. Through its focus on protein degradation, Zhiben Pharma seeks to provide next-generation therapeutic options for patients with refractory diseases.